New drug PM14 tested in patients with advanced cancers

NCT ID NCT05076396

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This early-stage trial tested a new drug called PM14 in 126 people with advanced solid tumors that had not responded to standard treatments. The main goals were to find the safest dose and to see if the drug could shrink tumors. The study is now complete, and results will help guide future research.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Clinica Universidad de Navarra

    Madrid, Madrid, 28027, Spain

  • Gustave Roussy

    Villejuif, París, 94805, France

  • Hospital General Universitario Gregorio Marañón

    Madrid, Madrid, 28007, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Catalonia, 08035, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Madrid, 28041, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Madrid, 28040, Spain

  • Hospital Universitario Madrid Sanchinarro

    Madrid, Madrid, 28050, Spain

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

Conditions

Explore the condition pages connected to this study.